Journal of Affective Disorders
July 15, 2026
Iman Kiani, Giulia Cattarinussi, Fabio Sambataro et al.
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant portion of patients experiencing treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, has shown promise in alleviating symptoms of TRD and suicidality, but variability in treatment response remains a challenge. Identifying neuroimaging biomarkers that predict responsiveness...
Journal of Affective Disorders
February 1, 2025
Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al.
4 citations
Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...
EClinicalMedicine
September 8, 2023
Mathilde Argote, Guillaume Sescousse, Jérôme Brunelin et al.
31 citations
Background: The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important...
Journal of Visualized Experiments
August 18, 2020
Giuseppe Delvecchio, Lucio Oldani, Gian Mario Mandolini et al.
3 citations
Cannabis is the illicit drug most commonly used worldwide, and its consumption can both induce psychiatric symptoms in otherwise healthy subjects and unmask a florid psychotic picture in patients with a prior psychotic risk. Previous studies suggest that chronic and long-term cannabis exposure may exert significant negative effects in brain areas enriched with cannabinoid receptors. However,...